Biotherapeutics, often known as "biologics pharmaceuticals," are drugs that are made from living organisms or contain elements of living organisms. In recent years, the worldwide biopharma industry has witnessed a rapidly advancing trend toward these drugs.
Biologics have become a primary focus for the majority of pharmaceutical companies due to its capacity to successfully treat complicated health problems like cancer, infectious disorders, and autoimmune diseases.
A significant shift from the discovery and production of monoclonal antibodies (mAbs) to multispecific formats, such as bispecific and trispecific antibodies, antibody fragments, antibody-drug conjugates (ADCs), and other immunoconjugates is being driven by the emergence of new generations of biologically engineered antibody drugs.
Bispecific antibodies (BsAbs) are employed in cancer immunotherapy because they have various advantages over single antibodies when they bind several epitopes.
BsAbs are made to simultaneously target and engage with two distinct surface antigens. As a result, they offer greater binding specificity in comparison to monospecific Abs and can also cause greater cytotoxicity by directing particular immune system effectors at tumour cells.
With ADCs, cytotoxic drugs are attached to antibodies, which are then used as carriers to deliver the toxic payloads to the targeted tumour cells.
To treat different tumours, researchers are combining formats like BsAbs and ADCs to create more complex, novel structures with greatly increased specificity and effectiveness. But as complexity grows, so do the difficulties in developing it and the concerns about patient safety.
Next-generation biotherapeutics have a lot of potential as medicines, but they also present a number of difficulties during the engineering, development, analytical characterization, and manufacturing stages. Differences in complex biologics can have an impact on a variety of factors, including how difficult and stable the molecules are to make and how well patients will finally tolerate these medications.
From Immunogenicity, to Stability issues to Other difficulties in manufacturing and purification of next-generation biologics, join industry experts on March 28–29, 2023 at the Steigenberger Airport Hotel, Berlin, Germany as they discuss Drug Safety and Efficacy of Complex Next-generation Biologics.
To register or learn more about the Forum please check here: https://bit.ly/3zxguXW.
For more information and group participation, contact us: [email protected]
